Bausch Health Adds Late-Stage Ready Alcohol Liver Disease Drug Candidate In $63 Million DURECT Buyout
Bausch Health Companies Inc. (NYSE:BHC) on Tuesday agreed to indirectly acquire DURECT Corp (NASDAQ:DRRX), including a novel therapeutic molecule, larsucosterol.
Benzinga ·